Fig. 4

Identification of AR’s target genes Wee1 and Lfng in Sertoli cells. A IGV snapshots showing AR binding peaks in Wee1 and Lfng genes. B Enrichment of AR at the promoter regions of Wee1 and Lfng confirmed by ChIP-qPCR. C Relative expression levels of Wee1, Lfng, Gdnf, and Ar in Sertoli cells treated with 0 and 10 μM enzalutamide, as determined by RT-PCR. D RT-PCR analysis of proliferation-associated genes (p19, p21, Cdk1, Cdk2, Ccnd1, Ccnd3, Pcna) in Sertoli cells treated with DMSO or 10 μM enzalutamide. E Relative expression levels of genes in the Wnt signaling pathway (Apc, Apc2, β-catenin, Axin2, Fzd1, Fzd2, Dkk3, Cacybp) in DMSO or 10 μM enzalutamide-treated Sertoli cells, determined by RT-PCR. F Relative expression levels of genes in the JAK-STAT signaling pathway (Jak2, Stat1, Stat3, Pias1, Pias2, Socs2) in DMSO or 10 μM enzalutamide-treated Sertoli cells assessed by RT-PCR. G Protein levels of AR, WEE1, PCNA, JAK2, STAT3, and phosphorylation of STAT3 in DMSO or 10 μM enzalutamide-treated Sertoli cells detected by Western blotting. H Statistical representation of Western blotting results. Results are presented as mean ± SD, with significance levels indicated by n.s. p > 0.05, *p < 0.05, **p < 0.01